Protalix BioTherapeutics (PLX) Cash from Operations Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Protalix BioTherapeutics |
176.47 Mn |
165.67 Mn |
29.62 Mn |
535.45% |
| Date | Value |
|---|
| Mar 31, 2026 |
535.45% |
| Dec 31, 2025 |
-49.14% |
| Sep 30, 2025 |
-190.91% |
| Jun 30, 2025 |
-44.96% |
| Mar 31, 2025 |
-220.77% |
| Dec 31, 2024 |
11.02% |
| Sep 30, 2024 |
159.60% |
| Jun 30, 2024 |
-172.59% |
| Mar 31, 2024 |
239.69% |
| Dec 31, 2023 |
237.69% |
| Sep 30, 2023 |
25.16% |
| Jun 30, 2023 |
167.60% |
| Mar 31, 2023 |
48.57% |
| Dec 31, 2022 |
48.67% |
| Sep 30, 2022 |
-389.57% |
| Jun 30, 2022 |
-212.89% |
| Mar 31, 2022 |
40.73% |
| Dec 31, 2021 |
32.62% |
| Sep 30, 2021 |
47.84% |
| Jun 30, 2021 |
183.17% |
